These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36507504)

  • 1. Development of curative therapies for sickle cell disease.
    Tanhehco YC; Nathu G; Vasovic LV
    Front Med (Lausanne); 2022; 9():1055540. PubMed ID: 36507504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease.
    Limerick E; Fitzhugh C
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31731790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy.
    Kassim AA; Leonard A
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
    Talano JA; Cairo MS
    Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?
    Tanhehco YC; Bhatia M
    Curr Opin Hematol; 2019 Nov; 26(6):448-452. PubMed ID: 31483336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the diagnosis and treatment of sickle cell disease.
    Brandow AM; Liem RI
    J Hematol Oncol; 2022 Mar; 15(1):20. PubMed ID: 35241123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curative Therapies for Sickle Cell Disease.
    Khemani K; Katoch D; Krishnamurti L
    Ochsner J; 2019; 19(2):131-137. PubMed ID: 31258425
    [No Abstract]   [Full Text] [Related]  

  • 11. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?
    Leonard A; Tisdale J; Abraham A
    Br J Haematol; 2020 May; 189(3):408-423. PubMed ID: 32034776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis.
    Aydin M; Dovern E; Leeflang MMG; de la Fuente J; Kassim AA; Biemond BJ; Nur E
    Transplant Cell Ther; 2021 Dec; 27(12):1004.e1-1004.e8. PubMed ID: 34537420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease.
    Bhatt S; Argueta DA; Gupta K; Kundu S
    Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene Therapies for Sickle Cell Disease.
    Weaver SB; Singh D; Wilson KM
    J Pharm Technol; 2024 Oct; 40(5):236-247. PubMed ID: 39391326
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
    Gluckman E; Cappelli B; Scigliuolo GM; De la Fuente J; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):181-188. PubMed ID: 32201153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease.
    Inam Z; Tisdale JF; Leonard A
    Expert Rev Hematol; 2023; 16(11):879-903. PubMed ID: 37800996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of sickle cell disease - options and perspective.
    Abdel-Hadi L; Ventura Carmenate Y; Castillo-Aleman YM; Sheikh S; Zakaria A; Phillips J
    Am J Blood Res; 2023; 13(2):61-70. PubMed ID: 37214647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review.
    Bhalla N; Bhargav A; Yadav SK; Singh AK
    Front Med (Lausanne); 2023; 10():1036939. PubMed ID: 36910492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.